Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A422

Breast Cancer Research and Treatment

Volumn 145, Issue 2, 2014, Pages 419-428

  Baxter, Simon D ^a   Teft, Wendy A ^a   Choi, Yun Hee ^b   Winquist, Eric ^b   Kim, Richard B ^a,b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Breast cancer; CYP3A4; Endoxifen; Hot flash; Pharmacogenomics; Tamoxifen

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; ENDOXIFEN; TAMOXIFEN; 4-HYDROXY-N-DESMETHYLTAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; BREAST CANCER; CANCER PATIENT; CONSTIPATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HOT FLUSH; HUMAN; LIQUID CHROMATOGRAPHY; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MENOPAUSE; METABOLITE; MOOD DISORDER; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SELF REPORT; SLEEP DISORDER; TANDEM MASS SPECTROMETRY; VERY ELDERLY; XEROSTOMIA; ANALOGS AND DERIVATIVES; BLOOD; BREAST NEOPLASMS; CHEMICALLY INDUCED; GENETICS; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; SELF REPORT; TAMOXIFEN;

EID: 84901690794     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2963-1     Document Type: Article

References (33)

1. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717 (Pubitemid 40719106)
2. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A (2007) Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272-282 (Pubitemid 47073490)
3. Lim YC, Desta Z, Flockhart DA, Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471-478 (Pubitemid 40568978)
4. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39
5. Murdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching PA, Fehm T, Eichelbaum M, Schwab M, Brauch H (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708-717
6. Teft WA, Gong IY, Dingle B, Potvin K, Younus J, Vandenberg TA, Brackstone M, Perera FE, Choi YH, Zou G, Legan RM, Tirona RG, Kim RB (2013) CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res Treat 139:95-105
7. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74 (Pubitemid 43946844)
8. Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L, Pierce JP (2008) Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat 108:421-426 (Pubitemid 351431079)
9. Henry NL, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z, Sikora MJ, Philips S, Nguyen AT, Storniolo AM, Hayes DF, Flockhart DA, Stearns V (2009) Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat 117:571-575
10. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318
11. Madlensky L, Flatt SW, Natarajan L, Lawrence H, Nikoloff D, Fontecha M, Hao S, Hillman G, Johnson A, Parker BA, Pierce JP (2009) Hof flashes are associated with CYP2D6 genotype in breast cancer survivors taking tamoxifen. Cancer Res 69:Abstract nr 6045
12. Bonanni B, Macis D, Maisonneuve P, Johansson HA, Gucciardo G, Oliviero P, Travaglini R, Muraca MG, Rotmensz N, Veronesi U, Decensi AU (2006) Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 24:3708-3709 author reply 3709 (Pubitemid 46630548)
13. Irvin WJ Jr, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST, Raab RE, Corso SW, Peppercorn JM, Anderson SM, Friedman KJ, Ogburn ET, Desta Z, Flockhart DA, McLeod HL, Evans JP, Carey LA (2011) Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: A multicenter study. J Clin Oncol 29:3232-3239
14. Lorizio W, Wu AH, Beattie MS, Rugo H, Tchu S, Kerlikowske K, Ziv E (2012) Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat 132:1107-1118
15. Sestak I, Kealy R, Nikoloff M, Fontecha M, Forbes JF, Howell A, Cuzick J (2012) Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. Br J Cancer 107:230-233
16. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AH, Pierce JP (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89:718-725
17. Gallicchio L, Lord G, Tkaczuk K, Danton M, Lewis LM, Lim CK, Flaws JA (2004) Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer. Breast Cancer Res Treat 85:89-97 (Pubitemid 38437985)
18. Jager NG, Koornstra RH, Vincent AD, van Schaik RH, Huitema AD, Korse TM, Schellens JH, Linn SC, Beijnen JH (2013) Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites. BMC Cancer 13:612
19. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W (2011) Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 11:274-286
20. Tsuchiya Y, Nakajima M, Yokoi T (2005) Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 227:115-124 (Pubitemid 41174580)
21. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H (2001) Methodologic lessons learned from hot flash studies. J Clin Oncol 19:4280-4290 (Pubitemid 33096775)
22. R Core Team (2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
23. Perez DG, Zahasky KM, Loprinzi CL, Sloan J, Novotny P, Barton D, Pritchard KI (2007) Tamoxifen-associated hot flashes in women. Support Cancer Ther 4:152-156 (Pubitemid 47113854)
24. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Bolander J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429-1436
25. Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O, Lang A, Offner F, Reynolds CA, Weinshilboum RM, Ames MM, Ingle JN (2013) CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res 19:500-507
26. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thurlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 104:441-451
27. Higgins MJ, Stearns V (2011) Pharmacogenetics of endocrine therapy for breast cancer. Annu Rev Med 62:281-293
28. Elens L, van Gelder T, Hesselink DA, Haufroid V, van Schaik RH (2013) CYP3A422: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics 14:47-62
29. Cho YA, Lee W, Choi JS (2012) Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin. Pharmazie 67:124-130
30. Li C, Kim M, Choi H, Choi J (2011) Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein. Arch Pharm Res 34:1965-1972
31. Binkhorst L, van Gelder T, Loos WJ, de Jongh FE, Hamberg P, Moghaddam-Helmantel IM, de Jonge E, Jager A, Seynaeve C, van Schaik RH, Verweij J, Mathijssen RH (2012) Effects of CYP induction by rifampicin on tamoxifen exposure. Clin Pharmacol Ther 92:62-67
32. Andrikoula M, Prelevic G (2009) Menopausal hot flushes revisited. Climacteric 12:3-15
33. Rebbeck TR, Su HI, Sammel MD, Lin H, Tran TV, Gracia CR, Freeman EW (2010) Effect of hormone metabolism genotypes on steroid hormone levels and menopausal symptoms in a prospective population-based cohort of women experiencing the menopausal transition. Menopause 17:1026-1034